Subcutaneous hydrocortisone infusion has been shown in studies to be “a safe and well-tolerated modality of cortisol replacement” (Nella et al 2016). Additionally, it is viewed as “a safe and reliable mode of glucocorticoid replacement and thus an attractive treatment option in selected patients” (Øksnes et al 2014). However no treatment is without any risk.
Below, we shall explore some of the more common risks associated with using a cortisol pump.
Find out more:
Cellulitis. (2018, April 10). Retrieved from https://www.mayoclinic.org/diseases-conditions/cellulitis/symptoms-causes/syc-20370762.
Insulin Pumps and Infections. (n.d.). Retrieved from http://www.diabetesforecast.org/2008/jan/insulin-pumps-and-infections.html.
Øksnes, M., Björnsdottir, S., Isaksson, M., Methlie, P., Carlsen, S., Nilsen, R. M., … Løvås, K. (2014). Continuous Subcutaneous Hydrocortisone Infusion versus Oral Hydrocortisone Replacement for Treatment of Addisons Disease: A Randomized Clinical Trial. The Journal of Clinical Endocrinology & Metabolism, 99(5), 1665–1674. doi: 10.1210/jc.2013-4253
Nella, A. A., Mallappa, A., Perritt, A. F., Gounden, V., Kumar, P., Sinaii, N., … Merke, D. P. (2016). A Phase 2 Study of Continuous Subcutaneous Hydrocortisone Infusion in Adults With Congenital Adrenal Hyperplasia. The Journal of Clinical Endocrinology & Metabolism, 101(12), 4690–4698. doi: 10.1210/jc.2016-1916